Hidden Coronary Threat: Microvascular Dysfunction Drives Heart Disease Beyond Blocked Arteries
A Lancet review spotlights how small vessel dysfunction silently worsens atherosclerotic coronary disease, reshaping diagnosis and treatment.
Summary
Most cardiology attention focuses on large blocked arteries, but the tiny blood vessels supplying the heart muscle can fail independently — and this matters enormously. This Lancet review by Escaned and Mejía-Rentería examines microvascular dysfunction as a distinct and underappreciated driver of atherosclerotic coronary disease. The coronary microcirculation, comprising vessels too small to stent or bypass, can become impaired in structure and function alongside or even before visible plaque buildup. This dysfunction reduces blood flow reserve, causes angina, and worsens outcomes even after successful treatment of larger blockages. The authors likely synthesize current evidence on assessment tools, mechanisms, and emerging therapeutic targets. For clinicians and health-conscious patients alike, this signals that a normal coronary angiogram does not rule out significant heart disease driven at the microvascular level.
Detailed Summary
Coronary artery disease has long been framed around visible plaque in large vessels, but a growing body of evidence reveals that the microcirculation — vessels smaller than 500 micrometers — plays a pivotal and independent role in cardiac health and disease. This Lancet review by Escaned and Mejía-Rentería brings critical attention to microvascular dysfunction as a key, often overlooked component of atherosclerotic coronary disease.
The coronary microcirculation is responsible for regulating blood flow to the heart muscle in response to demand. When these small vessels malfunction — whether through structural remodeling, impaired vasodilation, or microvascular spasm — the heart becomes vulnerable to ischemia even in the absence of flow-limiting stenosis in large arteries. This explains why many patients continue to experience angina and adverse events after technically successful coronary interventions.
The review likely covers the pathophysiology of coronary microvascular dysfunction (CMD), including its interplay with atherosclerosis, endothelial injury, inflammation, and metabolic factors. It probably addresses how CMD is now measurable invasively using indices like the index of microcirculatory resistance (IMR) and coronary flow reserve (CFR), as well as emerging non-invasive approaches.
Clinically, recognizing CMD changes patient management: treatment may need to shift toward medical therapies targeting endothelial function, inflammation, or vasomotor tone rather than mechanical revascularization alone. CMD is particularly prevalent in women, diabetics, and hypertensive patients — groups historically undertreated for ischemic heart disease.
Caveats include that this summary is based on the abstract only, limiting detail on specific findings. Additionally, both authors disclose financial relationships with Abbott, a company that manufactures coronary physiology tools, which warrants consideration when interpreting the review's conclusions.
Key Findings
- Microvascular dysfunction can drive ischemia and symptoms even when large coronary arteries appear unobstructed.
- CMD may explain persistent angina in patients after technically successful coronary stenting or bypass.
- Invasive indices like IMR and CFR enable direct measurement of microcirculatory health during catheterization.
- Women, diabetics, and hypertensive patients face disproportionately high CMD burden and are often underdiagnosed.
- Therapeutic strategies for CMD differ from revascularization and may include endothelial-targeted and anti-inflammatory agents.
Methodology
This is a narrative or systematic review article published in The Lancet, authored by two interventional cardiologists from Hospital Clínico San Carlos, Madrid. The review synthesizes existing evidence on microvascular dysfunction in the context of atherosclerotic coronary disease. Specific inclusion criteria, literature search strategy, and data pooling methods are not available from the abstract alone.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; specific data, patient populations, and detailed conclusions cannot be verified. Both authors report honoraria from Abbott, a manufacturer of coronary physiology diagnostic tools, which may introduce perspective bias in a review covering those same diagnostic indices. The review's scope, search methodology, and strength of evidence grading are unknown without full-text access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.